HC Wainwright Expects Lower Earnings for Leap Therapeutics

Leap Therapeutics, Inc. (NASDAQ:LPTX) – HC Wainwright decreased their Q1 2025 earnings estimates for shares of Leap Therapeutics in a report issued on Thursday, March 27th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.38) per share for the quarter, down from their prior estimate of ($0.34). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Leap Therapeutics’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Leap Therapeutics’ Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.26) EPS, FY2026 earnings at ($0.87) EPS, FY2027 earnings at ($0.80) EPS, FY2028 earnings at ($0.91) EPS and FY2029 earnings at ($0.37) EPS.

Leap Therapeutics (NASDAQ:LPTX) last posted its quarterly earnings results on Wednesday, March 26th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02.

Several other brokerages have also commented on LPTX. Robert W. Baird lowered shares of Leap Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $9.00 to $1.25 in a research note on Wednesday, January 29th. Baird R W downgraded shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 29th.

Leap Therapeutics Stock Performance

Shares of NASDAQ LPTX opened at $0.32 on Monday. The stock’s 50-day simple moving average is $0.69 and its 200-day simple moving average is $2.16. The firm has a market capitalization of $12.13 million, a PE ratio of -0.16 and a beta of 0.35. Leap Therapeutics has a fifty-two week low of $0.31 and a fifty-two week high of $4.79.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in LPTX. Gilead Sciences Inc. acquired a new stake in shares of Leap Therapeutics in the fourth quarter valued at approximately $15,293,000. Point72 Asset Management L.P. purchased a new stake in Leap Therapeutics in the 4th quarter valued at $4,025,000. Key Client Fiduciary Advisors LLC boosted its stake in Leap Therapeutics by 12.2% during the 4th quarter. Key Client Fiduciary Advisors LLC now owns 361,253 shares of the company’s stock worth $1,039,000 after purchasing an additional 39,330 shares during the period. Geode Capital Management LLC grew its position in Leap Therapeutics by 18.0% during the 3rd quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock worth $847,000 after purchasing an additional 50,194 shares during the last quarter. Finally, BIT Capital GmbH increased its stake in Leap Therapeutics by 248.2% in the fourth quarter. BIT Capital GmbH now owns 282,008 shares of the company’s stock valued at $811,000 after purchasing an additional 201,008 shares during the period. Hedge funds and other institutional investors own 30.46% of the company’s stock.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.